About: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.17 (-3.31%)
ANVS NYSE Annovis Bio Inc
Annovis Bio Inc share price
ANVS price activity
Last Price
$1.180
Change (24hr)
-0.03 USD (-2.48%)
Volume
803.51K
Volume (4w avg)
-
Open
$1.21
Day Range
$1.14 - $1.21
Previous Close
$1.21
Last Trade
08 Oct, 8:06 pm GMT+0
Delayed
08 Oct, 8:06 pm GMT+0
ANVS price performance
Delayed
08 Oct, 8:06 pm GMT+0
ANVS Market Signals